AI assistant
HAEMONETICS CORP — Director's Dealing 2025
Jun 3, 2025
31565_dirs_2025-06-03_93bc14c9-0ac9-4d68-9cc3-ed7c36c697fd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2025-05-30
Reporting Person: Basil Michelle L (EVP and General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-30 | Common Stock | A | 15554 | — | Acquired | 49721 | Direct |
| 2025-05-30 | Common Stock | F | 7469 | $69.38 | Disposed | 42252 | Direct |
Footnotes
F1: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.
F2: This number includes unvested restricted stock units ("RSUs") previously reported.
F3: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.